{
    "organizations": [],
    "uuid": "85dbbc3b002608d61d8939b675897dc4ae3ad8dc",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-nanobiotix-partners-with-the-provi/brief-nanobiotix-partners-with-the-providence-cancer-institute-to-run-immunotherapeutic-preclinical-research-in-pancreatic-cancers-idUSFWN1P6011",
    "ord_in_thread": 0,
    "title": "BRIEF-Nanobiotix Partners With The Providence Cancer Institute To Run Immunotherapeutic Preclinical Research In Pancreatic Cancers",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Jan 11 (Reuters) - NANOBIOTIX SA:\n* NANOBIOTIX PARTNERS WITH THE PROVIDENCE CANCER INSTITUTE TO RUN IMMUNOTHERAPEUTIC PRECLINICAL RESEARCH IN PANCREATIC CANCERS\n* COLLABORATION WILL TAKE PLACE OVER COURSE OF ONE YEAR * WILL LAUNCH ITS FIRST CLINICAL TRIAL COMBINING NBTXR3 WITH IMMUNE CHECKPOINT INHIBITORS IN U.S.\n* HAS RECEIVED APPROVAL OF ITS INVESTIGATIONAL NEW DRUG (IND Source text for Eikon: Further company coverage: (Gdynia Newsroom)\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-01-11T15:47:00.000+02:00",
    "crawled": "2018-01-12T18:43:19.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "jan",
        "reuters",
        "nanobiotix",
        "sa",
        "nanobiotix",
        "partner",
        "providence",
        "cancer",
        "institute",
        "run",
        "immunotherapeutic",
        "preclinical",
        "research",
        "pancreatic",
        "cancer",
        "collaboration",
        "take",
        "place",
        "course",
        "one",
        "year",
        "launch",
        "first",
        "clinical",
        "trial",
        "combining",
        "nbtxr3",
        "immune",
        "checkpoint",
        "inhibitor",
        "received",
        "approval",
        "investigational",
        "new",
        "drug",
        "ind",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}